November 12, 2012

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2012 ACS

Patent Number: US 8252927
Title: Synthesis of substituted 4-aminopyrimidines as intermediates of vitamin B1
Inventor(s): Karge, Reinhard; Letinois, Ulla; Schiefer, Gerhard
Patent Assignee(s): DSM IP Assets B.V., Neth.
Source: PCT Int. Appl., 28pp. CODEN: PIXXD2
Language: English

Abstract:
The present invention is directed to a process for the manufacture of 4-aminopyrimidines of formula I [R1 = amino protecting group; R2 = H, alkyl] via (a) reacting a compound of formula II [M+ = cation] with an ammonium salt to give III and (b) cyclization of III with an alkyl nitrile. The present invention is further directed to compds. of formula III and their use for the manufacture of vitamin B1.

View the full-text USPTO patent here.

Note: Titles and abstracts for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced both the abstract and title using additional information found in the patent. The original title of the U.S. granted patent is Synthesis of substituted 4-aminopyrimidines. For the CAplus record, this title was enhanced to read Synthesis of substituted 4-aminopyrimidines as intermediates of vitamin B1.

Recent News


    June 29, 2015 | CAS Assigns the 100 Millionth CAS
    Registry Number to a Substance Designed to
    Treat Acute Myeloid Leukemia
   
    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value

    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    Professionals

                                                                       More News >> 
 
 

Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624
 Email: cas-pr@cas.org